1
|
Chen H, Modiano MR, Neal JW, Brahmer JR, Rigas JR, Jotte RM, Leighl NB, Riess JW, Kuo CJ, Liu L, Gao B, Dicioccio AT, Adjei AA, Wakelee HA. A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. Br J Cancer 2013; 110:602-8. [PMID: 24292447 PMCID: PMC3915116 DOI: 10.1038/bjc.2013.735] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2013] [Revised: 10/27/2013] [Accepted: 10/30/2013] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND This study evaluated the efficacy and safety of ziv-aflibercept in combination with cisplatin and pemetrexed in non-small cell lung cancer (NSCLC). METHODS This single arm, multicentre phase II trial enrolled patients with previously untreated, locally advanced or metastatic non-squamous NSCLC. Patients received intravenous ziv-aflibercept 6 mg kg(-1), pemetrexed 500 mg m(-2), and cisplatin 75 mg m(-2), every 21 days for up to six cycles. Maintenance administration of ziv-aflibercept was to continue until disease progression, intolerable toxicity or other cause for withdrawal. The co-primary end points were objective response rate (ORR) and progression-free survival (PFS). Planned sample size was 72 patients. RESULTS The study was closed prematurely because of three confirmed and two suspected cases of reversible posterior leukoencephalopathy syndrome (RPLS). A total of 42 patients were enrolled. Median age was 61.5 years; 55% were male, 86% Caucasian and 50% had Eastern Cooperative Oncology Group performance status (ECOG PS)=0. A median of four cycles of ziv-aflibercept was administered. The most common treatment-emergent adverse events (TEAEs) of any grade were nausea (69%) and fatigue (67%), with hypertension (36%) as the most common grade 3/4 TEAE. Of the 38 evaluable patients, ORR was 26% and median PFS was 5 months. CONCLUSION Cases of RPLS had been observed in other studies in the ziv-aflibercept clinical development programme but the rate observed in this study was higher than previously observed. This might be related to declining renal function and/or hypertension. Although ORR and PFS were in accordance with most historical first-line NSCLC studies, this combination of ziv-aflibercept/cisplatin/pemetrexed will not be further explored in NSCLC.
Collapse
Affiliation(s)
- H Chen
- Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA
| | - M R Modiano
- Arizona Oncology/Arizona Clinical Research Center, 1620W. St Mary's Rd, Tucson, AZ 85745, USA
| | - J W Neal
- Department of Medicine, Stanford University School of Medicine and Cancer Institute, 875 Blake Wilbur Dr, Stanford, CA 94305, USA
| | - J R Brahmer
- Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting/Blaustein CRB, 1650 Orleans St., G94, Baltimore, MD 21231, USA
| | - J R Rigas
- Department of Medicine, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, 1 Medical Center Drive, Lebanon, NH 03756, USA
| | - R M Jotte
- Rocky Mountain Cancer Centers, 1800 Williams Street, Suite 200, Denver, CO 80218, USA
| | - N B Leighl
- Department of Medicine, Princess Margaret Hospital and University of Toronto, 610 University Avenue, Toronto, ON M5G 2M9, Canada
| | - J W Riess
- Department of Medicine, Stanford University School of Medicine and Cancer Institute, 875 Blake Wilbur Dr, Stanford, CA 94305, USA
| | - C J Kuo
- Department of Medicine, Stanford University School of Medicine and Cancer Institute, 875 Blake Wilbur Dr, Stanford, CA 94305, USA
| | - L Liu
- Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
| | - B Gao
- Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
| | - A T Dicioccio
- Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
| | - A A Adjei
- Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA
| | - H A Wakelee
- Department of Medicine, Stanford University School of Medicine and Cancer Institute, 875 Blake Wilbur Dr, Stanford, CA 94305, USA
| |
Collapse
|
2
|
Dragnev KH, Ma T, Galimberti F, Erkmen CP, Memoli V, Nugent W, Rigas JR, Johnstone D, Frandsen A, Simeone S, Czum J, Li H, DiRenzo J, Freemantle S, Dmitrovsky E. A window-of-opportunity trial of vorinostat (V) in patients with resectable non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
3
|
Rigas JR, Schuster M, Orlov SV, Milovanovic B, Prabhash K, Smith JT. Efect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II randomized, double-blind safety and efficacy trial. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7622] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
4
|
Schuster M, Rigas JR, Orlov SV, Milovanovic B, Prabhash K, Smith JT. ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II, randomized, double-blind, placebo-controlled trial. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7631] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
5
|
Gerber SA, Kettenbach AN, Schweppe DK, Dragnev KH, Rigas JR. Use of quantitative proteomics to evaluate substrates and functional modules of the aurora and polo-like kinases. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e13530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
6
|
Slagle BM, Rigas JR, Dragnev KH, Williams I, DiSalvo W, Engman C, Lipe B, Simeone S. Dose-ranging study of the combination of paclitaxel poliglumex and pemetrexed in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19090 Background: Taxanes continue to play an important role in the treatment of advanced NSCLC. Paclitaxel poliglumex (XyotaxTM) is an ester α-poly-L-glutamic acid conjugate of paclitaxel allowing for solubility in aqueous solution, not requiring Cremophor or ethanol for intravenous administration or premedications. This is a non-randomized single-arm, single-institution open label dose-ranging study was designed to evaluate the combination of pemetrexed and paclitaxel poliglumex. Methods: The primary objective of this study was to evaluate the safety of this combination. Patients (pts) were enrolled in 2 different dosing levels. The first 6 received 135 mg/m2 paclitaxel poliglumex and 500 mg/m2 pemetrexed intravenously every 3 wks. None of the 6 pts experienced an initial dose limiting toxicity (IDLT) following 2 cycles of therapy and the paclitaxel poliglumex was then escalated to 175 mg/m2 with 500 mg/m2 pemetrexed. Eligibility included advanced NSCLC, one or more measurable lesions (RECIST), ECOG = 0–2, prior chemotherapy and radiation allowed, no grade 2+ peripheral neuropathy, no untreated brain metastases, and no active cardiac disease. Results: Twelve pts were enrolled, 6 pts to each dose level. Four of the pts were female, the median age was 65 years (48- 74), 11 had a performance status of 0–1, and only 1 pt received prior chemotherapy. There were no IDLTs at the first dose level, and there was one IDLT of infection with neutropenia at the second dose level. The median number of cycles completed was 5 (range 1–12 cycles). Aside from grade 3 fatigue in 2 pts there were no grade 3 or greater non-hematologic toxicities. Common non-hematologic toxicities included peripheral neuropathy, constipation, fatigue, and alopecia. Of the 12 pts, the best response was stable disease in 9 pts, 2 are without disease progression, and 6 pts are alive to date. The median progression free survival was 3.3 months (range 0.7–10.7 months). Conclusions: The combination of paclitaxel poliglumex and pemetrexed was well tolerated at the proposed phase II dose of 175 mg/m2 and 500 mg/m2. The PFS is encouraging and future studies of this combination are recommended. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- B. M. Slagle
- Dartmouth- Hitchcock Medical Center, Lebanon, NH
| | - J. R. Rigas
- Dartmouth- Hitchcock Medical Center, Lebanon, NH
| | | | - I. Williams
- Dartmouth- Hitchcock Medical Center, Lebanon, NH
| | - W. DiSalvo
- Dartmouth- Hitchcock Medical Center, Lebanon, NH
| | - C. Engman
- Dartmouth- Hitchcock Medical Center, Lebanon, NH
| | - B. Lipe
- Dartmouth- Hitchcock Medical Center, Lebanon, NH
| | - S. Simeone
- Dartmouth- Hitchcock Medical Center, Lebanon, NH
| |
Collapse
|
7
|
Dragnev KH, Cyrus JC, Rigas JR, DiSalvo WM, Dmitrovsky E. Association between triglyceride (TG) levels, other clinical characteristics, and outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with erlotinib and bexarotene. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8101 Background: Studies of the nonclassical retinoid bexarotene (B) alone or in combination with chemotherapy have revealed improved survival for a subset of NSCLC patients (pts) who developed hypertrigyceridemia despite treatment with antilipid agents. It is not known if a similar association exists when B is combined with a targeted agent. We have completed 2 trials of erlotinib (E), and B, in pts with advanced NSCLC showing minimal toxicities and evidence of clinical activity. In both trials atorvastatin was begun only after elevated TG were detected. This approach differed from other studies where statin therapy was initiated concurrently with B. Methods: E 150 mg and B 400 mg/m2 were administered daily orally to pts with stage IV NSCLC, mostly as third line or higher. Atorvastatin 20 mg was started for elevated fasting TG. The dose was increased to 40 mg if hypertriglyceridemia persisted, followed by the addition of fenofibrate and/or dose reductions of B to 300 mg/m2. TG levels assessed in the first 4 weeks were correlated with overall survival. The appearance of skin rash was documented. Results: Sixty-one pts with stage IV NSCLC were enrolled, 54% women and 72% with adenocarcinoma, 15% never smokers, 20% current smokers, 15% had prior anti-EGFR therapy. Median survival time (MST) was 22 (1–274) wks (intent-to-treat). For pts with elevated TG, the MST was 24 (1–274) wks, while for pts with normal TG the MST was 21 (4–72). There was a statistically significant correlation between TG levels and survival, Spearman's correlation coefficient 0.48, p=0.0003. We will present the analysis of the association between outcomes and other clinical characteristics. Conclusions: Development of hypertriglyceridemia in the first 4 weeks of therapy with E and B in the absence of antilipid treatment is associated with increased overall survival. These findings implicate clinical benefit of dual targeting of EGFR and cyclin D1 especially in a subset of NSCLC pts with elevated TG early in therapy. Further work to identify the molecular basis for this association is needed to allow selection of pts more likely to benefit from this combined therapy. [Table: see text]
Collapse
Affiliation(s)
- K. H. Dragnev
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; Dartmouth Medical School, Hanover, NH
| | - J. C. Cyrus
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; Dartmouth Medical School, Hanover, NH
| | - J. R. Rigas
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; Dartmouth Medical School, Hanover, NH
| | - W. M. DiSalvo
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; Dartmouth Medical School, Hanover, NH
| | - E. Dmitrovsky
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; Dartmouth Medical School, Hanover, NH
| |
Collapse
|
8
|
Abrey LE, Wen P, Govindan R, Reimers H, Rigas JR, Robins HI, Allen-Freda E, Gao B, Ko J, Johri A. Patupilone for the treatment of recurrent/progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): An open-label phase II study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.2033] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Rigas JR, Carey M, Dragnev KH, Simeone SA, Page RD, Rubin MS, Ghazal H. Phase III multicenter web-based study demonstrating survival equivalents of nonplatinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC): Subgroup analysis from D0112. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8100] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
10
|
Dragnev KH, Rigas JR, Seltzer M, DiSalvo W, Simeone S, Johnstone D, Nugent W, Dmitrovsky E. A phase II clinical and PET study of erlotinib and bexarotene for heavily pretreated advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.19079] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
11
|
Ho L, Li T, Piperdi B, Macapinlac M, Rigas JR, Camacho F, Perez-Soler R, Gucalp R. Phase II study to evaluate the efficacy and safety of bortezomib (PS-341) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.19096] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Smylie M, Blumenschein GR, Dowlati A, Garst J, Shepherd FA, Rigas JR, Hassani H, Berger MS, Zaks T, Ross HJ. A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma (BAC) or no smoking history. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.7611] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7611 Background: LAP (GW572016) is an oral reversible, dual tyrosine kinase inhibitor of EGFR (ERBB1) and HER2/neu (ERBB2). This study was designed to test the activity of 2 dose schedules of LAP in chemotherapy naïve pts with NSCLC; it was amended to target patients with either BAC or no smoking history in the first or second line and to evaluate the relationship of mutations in target genes to responses. Methods: LAP was given orally 1,500 mg once (QD) or 500 mg twice daily (BID) until progression or intolerance. Safety and efficacy (RECIST) were assessed every 4 & 8 weeks. The primary endpoint was response. The target (BAC/no smoking) and non- target populations were assessed for efficacy, and tumor tissue was analyzed for ERBB1 and ERBB2 mutations and/or amplifications. Results: The study was stopped for futility after 131 pts were randomized (65 QD, 66 BID). Median age 66 (range 32–86); female 56%; BAC 20%, No BAC 71%; previously untreated 98.5%; current/former smokers 70%, never smoker 30%. There were no complete responses. Of 56 pts in the target population, 1 (2%) achieved partial response (PR), 11 (20%) had stable disease (SD) of ≥24 wks; in the non-target population, 1 pt had a PR (1.3%) and 12 (16%) had SD of ≥24 wks. 3 pts had ERBB1 mutations (G719S, S768I, KRAS G12S; L858R and T790M; L858R) but none of them responded. There were no ERBB2 mutations. Three of 77 pts evaluated had ERBB1 gene copy increase (none of whom responded) and 2 had ERBB2 gene copy increase (one had a 51% decrease in tumor size). The most common adverse events were grade 1/2 diarrhea, nausea, rash, vomiting and fatigue, and were similar in both groups. Conclusions: LAP was well-tolerated, with no notable difference in toxicity between the QD and BID groups. Very few responses were seen, stable disease was sometimes prolonged. The prevalence of mutations was low even in the target population. Given the preclinical synergy between LAP and other agents, further studies will be necessary to determine whether LAP is active in combination with other agents for the treatment of NSCLC. [Table: see text]
Collapse
Affiliation(s)
- M. Smylie
- University of Alberta, Edmonton, AB, Canada; University of Texas M.D. Anderson Cancer Center, Houston, TX; University Hospitals of Cleveland, Cleveland, OH; Duke University Medical Center, Durham, NC; Princess Margaret Hospital, Toronto, ON, Canada; Dartmouth Hitchcock Medical Center, Lebanon, NH; GlaxoSmithKline, Collegeville, PA; Earle A. Chiles Research Institute, Portland, OR
| | - G. R. Blumenschein
- University of Alberta, Edmonton, AB, Canada; University of Texas M.D. Anderson Cancer Center, Houston, TX; University Hospitals of Cleveland, Cleveland, OH; Duke University Medical Center, Durham, NC; Princess Margaret Hospital, Toronto, ON, Canada; Dartmouth Hitchcock Medical Center, Lebanon, NH; GlaxoSmithKline, Collegeville, PA; Earle A. Chiles Research Institute, Portland, OR
| | - A. Dowlati
- University of Alberta, Edmonton, AB, Canada; University of Texas M.D. Anderson Cancer Center, Houston, TX; University Hospitals of Cleveland, Cleveland, OH; Duke University Medical Center, Durham, NC; Princess Margaret Hospital, Toronto, ON, Canada; Dartmouth Hitchcock Medical Center, Lebanon, NH; GlaxoSmithKline, Collegeville, PA; Earle A. Chiles Research Institute, Portland, OR
| | - J. Garst
- University of Alberta, Edmonton, AB, Canada; University of Texas M.D. Anderson Cancer Center, Houston, TX; University Hospitals of Cleveland, Cleveland, OH; Duke University Medical Center, Durham, NC; Princess Margaret Hospital, Toronto, ON, Canada; Dartmouth Hitchcock Medical Center, Lebanon, NH; GlaxoSmithKline, Collegeville, PA; Earle A. Chiles Research Institute, Portland, OR
| | - F. A. Shepherd
- University of Alberta, Edmonton, AB, Canada; University of Texas M.D. Anderson Cancer Center, Houston, TX; University Hospitals of Cleveland, Cleveland, OH; Duke University Medical Center, Durham, NC; Princess Margaret Hospital, Toronto, ON, Canada; Dartmouth Hitchcock Medical Center, Lebanon, NH; GlaxoSmithKline, Collegeville, PA; Earle A. Chiles Research Institute, Portland, OR
| | - J. R. Rigas
- University of Alberta, Edmonton, AB, Canada; University of Texas M.D. Anderson Cancer Center, Houston, TX; University Hospitals of Cleveland, Cleveland, OH; Duke University Medical Center, Durham, NC; Princess Margaret Hospital, Toronto, ON, Canada; Dartmouth Hitchcock Medical Center, Lebanon, NH; GlaxoSmithKline, Collegeville, PA; Earle A. Chiles Research Institute, Portland, OR
| | - H. Hassani
- University of Alberta, Edmonton, AB, Canada; University of Texas M.D. Anderson Cancer Center, Houston, TX; University Hospitals of Cleveland, Cleveland, OH; Duke University Medical Center, Durham, NC; Princess Margaret Hospital, Toronto, ON, Canada; Dartmouth Hitchcock Medical Center, Lebanon, NH; GlaxoSmithKline, Collegeville, PA; Earle A. Chiles Research Institute, Portland, OR
| | - M. S. Berger
- University of Alberta, Edmonton, AB, Canada; University of Texas M.D. Anderson Cancer Center, Houston, TX; University Hospitals of Cleveland, Cleveland, OH; Duke University Medical Center, Durham, NC; Princess Margaret Hospital, Toronto, ON, Canada; Dartmouth Hitchcock Medical Center, Lebanon, NH; GlaxoSmithKline, Collegeville, PA; Earle A. Chiles Research Institute, Portland, OR
| | - T. Zaks
- University of Alberta, Edmonton, AB, Canada; University of Texas M.D. Anderson Cancer Center, Houston, TX; University Hospitals of Cleveland, Cleveland, OH; Duke University Medical Center, Durham, NC; Princess Margaret Hospital, Toronto, ON, Canada; Dartmouth Hitchcock Medical Center, Lebanon, NH; GlaxoSmithKline, Collegeville, PA; Earle A. Chiles Research Institute, Portland, OR
| | - H. J. Ross
- University of Alberta, Edmonton, AB, Canada; University of Texas M.D. Anderson Cancer Center, Houston, TX; University Hospitals of Cleveland, Cleveland, OH; Duke University Medical Center, Durham, NC; Princess Margaret Hospital, Toronto, ON, Canada; Dartmouth Hitchcock Medical Center, Lebanon, NH; GlaxoSmithKline, Collegeville, PA; Earle A. Chiles Research Institute, Portland, OR
| |
Collapse
|
13
|
Abrey L, Wen PY, Govindan R, Reimers HJ, Rigas JR, Robins HI, de Bedout S, O’Connell C, Li X, Johri A. Activity of patupilone for the treatment of recurrent or progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): An open-label, multicenter, phase II study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18058] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18058 Background: Advances in systemic chemotherapy have improved overall survival for patients with advanced NSCLC; unfortunately, CNS metastasis is common and limits survival benefits with current therapies. Unlike taxanes, preclinical findings suggest that the novel epothilone, patupilone, crosses the blood-brain barrier in 3 animal species and also has antitumor effects in brain tumor models. Results of an ongoing phase I/II study of patupilone as second-line therapy in pts with NSCLC are encouraging. The present study is evaluating the efficacy of patupilone in pts with brain metastases from NSCLC who have failed or recurred after previous chemotherapy, surgery, and/or radiation to the brain. Methods: This open-label, single-arm, multicenter, phase II study has a 2-stage design (25 pts per stage). Eligible pts have histologically confirmed NSCLC and = 1 recurrent, bidimensionally measurable intracranial lesion = 2 cm. Patupilone was administered IV at 10 mg/m2 as a single 20-min IV infusion every 3 weeks until disease progression, satisfactory response, or unacceptable toxicity. The primary multinomial endpoint was a combination of early progression (disease progression or death before cycle 1, day 21) and response rate (alive without progression at cycle 4, day 1). Results: An interim analysis of 13 pts with a median age of 62 years (range, 40–67 years) is reported. The most common adverse events (AEs) related to study drug were NCI CTC grade 1/2 diarrhea in 7 (54%) pts, nausea in 3 (23%), and fatigue in 2 (15%). Only 2 serious AEs (grade 4 colitis and grade 3 diarrhea) and 2 additional grade 3 AEs (diarrhea, neutropenia) were reported in 1 pt each. Three (23%) pts experienced early disease progression. Five (38%) pts responded, receiving a median 10 cycles (range, 5 to 12 cycles) and were alive without progression on cycle 4, day 1. Conclusions: Patupilone has activity in patients with CNS metastases from advanced NSCLC and is well tolerated. Additional investigation of patupilone as a treatment for brain metastases from NSCLC is warranted. [Table: see text]
Collapse
Affiliation(s)
- L. Abrey
- Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; Washington University, St. Louis, MO; St. Louis University Cancer Center, St. Louis, MO; Dartmouth Hitchcock Medical Center, Lebanon, NH; University of Wisconsin, Madison, WI; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - P. Y. Wen
- Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; Washington University, St. Louis, MO; St. Louis University Cancer Center, St. Louis, MO; Dartmouth Hitchcock Medical Center, Lebanon, NH; University of Wisconsin, Madison, WI; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - R. Govindan
- Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; Washington University, St. Louis, MO; St. Louis University Cancer Center, St. Louis, MO; Dartmouth Hitchcock Medical Center, Lebanon, NH; University of Wisconsin, Madison, WI; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - H. J. Reimers
- Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; Washington University, St. Louis, MO; St. Louis University Cancer Center, St. Louis, MO; Dartmouth Hitchcock Medical Center, Lebanon, NH; University of Wisconsin, Madison, WI; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - J. R. Rigas
- Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; Washington University, St. Louis, MO; St. Louis University Cancer Center, St. Louis, MO; Dartmouth Hitchcock Medical Center, Lebanon, NH; University of Wisconsin, Madison, WI; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - H. I. Robins
- Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; Washington University, St. Louis, MO; St. Louis University Cancer Center, St. Louis, MO; Dartmouth Hitchcock Medical Center, Lebanon, NH; University of Wisconsin, Madison, WI; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - S. de Bedout
- Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; Washington University, St. Louis, MO; St. Louis University Cancer Center, St. Louis, MO; Dartmouth Hitchcock Medical Center, Lebanon, NH; University of Wisconsin, Madison, WI; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - C. O’Connell
- Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; Washington University, St. Louis, MO; St. Louis University Cancer Center, St. Louis, MO; Dartmouth Hitchcock Medical Center, Lebanon, NH; University of Wisconsin, Madison, WI; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - X. Li
- Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; Washington University, St. Louis, MO; St. Louis University Cancer Center, St. Louis, MO; Dartmouth Hitchcock Medical Center, Lebanon, NH; University of Wisconsin, Madison, WI; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - A. Johri
- Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; Washington University, St. Louis, MO; St. Louis University Cancer Center, St. Louis, MO; Dartmouth Hitchcock Medical Center, Lebanon, NH; University of Wisconsin, Madison, WI; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| |
Collapse
|
14
|
Rigas JR, Rubin MS, Waples JM, Dragnev KH, Zimmerman DM, Reimer RR, Droder R, Rathmann J, Green NB, Carey M. Safety assessment for the combination of docetaxel, carboplatin, and thoracic radiotherapy in unresectable stage III non-small cell lung cancer (NSCLC): A report of the first 100 patients treated with chemoradiation on D0410. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.7701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7701 Background: Concurrent chemoradiotherapy (chemoRT) is the preferred treatment for patients with unresectable stage III NSCLC. Limited safety information is available on the use of concurrent docetaxel, carboplatin and thoracic RT. We report the safety information on the initial 100 patients (pts) treated with this chemoRT as part of an ongoing US randomized phase III trial (D0410) evaluating the role of erlotinib/placebo following this concurrent chemoRT treatment. The sample size is 400 pts and the primary endpoint is progression-free survival. Methods: Pts with unresectable pathologically confirmed stage III NSCLC are randomized to receive either erlotinib 150 mg or placebo orally daily for 2 years following concurrent chemoRT with docetaxel 20 mg/m2, carboplatin AUC=2 intravenously weekly for 6 wks with thoracic RT of at least 61 Gy in 33 fractions over 6.5 weeks. The planned total lung volume exceeding 20 Gy (V20) was less than 32%. Only the chemoradiation safety information is being reported. This data was reviewed by an independent safety and data monitoring committee. Results: Pt characteristics; 59% males, median age 69 years (range 38 to 86), 21% adenocarcinoma, 48% squamous cell, 94% ECOG PS0–1, 49% stage IIIA, 15% weight loss = 10%. Of 600 planned chemotherapy treatments, 492 were administered (93 wk 1, 85 wk 2, 82 wk 3, 81 wk 4, 77 wk 5, 74 wk 6). There were 25 chemotherapy dose reductions; most commonly for esophagitis (8), neutropenia (5), renal dysfunction (3), hypersensitivity (2). There were no treatment-related deaths. There were 25 grade 3 and 3 grade 4 treatment-related adverse events. The most common grade 3/4 events were esophagitis (6), fatigue (3), odynophagia (2), neutropenia (1), thrombocytopenia (1), dematitis (1). Conclusions: This concurrent chemoradiation regimen appears to be safe. Enrollment to the phase III trial continues. There is a planned interim efficacy evaluation at 150 events (deaths or disease progression). Funded in part by Sanofi- Aventis, Genentech, and OSI Pharmaceuticals. [Table: see text]
Collapse
Affiliation(s)
- J. R. Rigas
- Dartmouth Medical School, Lebanon, NH; Florida Cancer Specialists, Bonita Springs, FL; Clearview Cancer Institute, Huntsville, AL; Fort Wayne Oncology/Hematology, Fort Wayne, IN; Olympic Hematology Oncology Associates, Bremerton, WA; Tyler Hematology/Oncology PA, Tyler, TX; St Francis Care Reg Cancer Center, Hartford, CT; Southeast Nebraska Hem and Onc Consult PC, Lincoln, NE
| | - M. S. Rubin
- Dartmouth Medical School, Lebanon, NH; Florida Cancer Specialists, Bonita Springs, FL; Clearview Cancer Institute, Huntsville, AL; Fort Wayne Oncology/Hematology, Fort Wayne, IN; Olympic Hematology Oncology Associates, Bremerton, WA; Tyler Hematology/Oncology PA, Tyler, TX; St Francis Care Reg Cancer Center, Hartford, CT; Southeast Nebraska Hem and Onc Consult PC, Lincoln, NE
| | - J. M. Waples
- Dartmouth Medical School, Lebanon, NH; Florida Cancer Specialists, Bonita Springs, FL; Clearview Cancer Institute, Huntsville, AL; Fort Wayne Oncology/Hematology, Fort Wayne, IN; Olympic Hematology Oncology Associates, Bremerton, WA; Tyler Hematology/Oncology PA, Tyler, TX; St Francis Care Reg Cancer Center, Hartford, CT; Southeast Nebraska Hem and Onc Consult PC, Lincoln, NE
| | - K. H. Dragnev
- Dartmouth Medical School, Lebanon, NH; Florida Cancer Specialists, Bonita Springs, FL; Clearview Cancer Institute, Huntsville, AL; Fort Wayne Oncology/Hematology, Fort Wayne, IN; Olympic Hematology Oncology Associates, Bremerton, WA; Tyler Hematology/Oncology PA, Tyler, TX; St Francis Care Reg Cancer Center, Hartford, CT; Southeast Nebraska Hem and Onc Consult PC, Lincoln, NE
| | - D. M. Zimmerman
- Dartmouth Medical School, Lebanon, NH; Florida Cancer Specialists, Bonita Springs, FL; Clearview Cancer Institute, Huntsville, AL; Fort Wayne Oncology/Hematology, Fort Wayne, IN; Olympic Hematology Oncology Associates, Bremerton, WA; Tyler Hematology/Oncology PA, Tyler, TX; St Francis Care Reg Cancer Center, Hartford, CT; Southeast Nebraska Hem and Onc Consult PC, Lincoln, NE
| | - R. R. Reimer
- Dartmouth Medical School, Lebanon, NH; Florida Cancer Specialists, Bonita Springs, FL; Clearview Cancer Institute, Huntsville, AL; Fort Wayne Oncology/Hematology, Fort Wayne, IN; Olympic Hematology Oncology Associates, Bremerton, WA; Tyler Hematology/Oncology PA, Tyler, TX; St Francis Care Reg Cancer Center, Hartford, CT; Southeast Nebraska Hem and Onc Consult PC, Lincoln, NE
| | - R. Droder
- Dartmouth Medical School, Lebanon, NH; Florida Cancer Specialists, Bonita Springs, FL; Clearview Cancer Institute, Huntsville, AL; Fort Wayne Oncology/Hematology, Fort Wayne, IN; Olympic Hematology Oncology Associates, Bremerton, WA; Tyler Hematology/Oncology PA, Tyler, TX; St Francis Care Reg Cancer Center, Hartford, CT; Southeast Nebraska Hem and Onc Consult PC, Lincoln, NE
| | - J. Rathmann
- Dartmouth Medical School, Lebanon, NH; Florida Cancer Specialists, Bonita Springs, FL; Clearview Cancer Institute, Huntsville, AL; Fort Wayne Oncology/Hematology, Fort Wayne, IN; Olympic Hematology Oncology Associates, Bremerton, WA; Tyler Hematology/Oncology PA, Tyler, TX; St Francis Care Reg Cancer Center, Hartford, CT; Southeast Nebraska Hem and Onc Consult PC, Lincoln, NE
| | - N. B. Green
- Dartmouth Medical School, Lebanon, NH; Florida Cancer Specialists, Bonita Springs, FL; Clearview Cancer Institute, Huntsville, AL; Fort Wayne Oncology/Hematology, Fort Wayne, IN; Olympic Hematology Oncology Associates, Bremerton, WA; Tyler Hematology/Oncology PA, Tyler, TX; St Francis Care Reg Cancer Center, Hartford, CT; Southeast Nebraska Hem and Onc Consult PC, Lincoln, NE
| | - M. Carey
- Dartmouth Medical School, Lebanon, NH; Florida Cancer Specialists, Bonita Springs, FL; Clearview Cancer Institute, Huntsville, AL; Fort Wayne Oncology/Hematology, Fort Wayne, IN; Olympic Hematology Oncology Associates, Bremerton, WA; Tyler Hematology/Oncology PA, Tyler, TX; St Francis Care Reg Cancer Center, Hartford, CT; Southeast Nebraska Hem and Onc Consult PC, Lincoln, NE
| |
Collapse
|
15
|
Petty WJ, Voelzke WR, Memoli VA, Dragnev KH, Urbanic JJ, Rigas JR, Dmitrovsky E. Expression of cyclin D3 confers resistance to erlotinib. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18054 Background: Transcriptional repression of cyclin D1 occurs during responses to erlotinib (E) both in vitro and in vivo. Cyclin D3 has overlapping function with cyclin D1 but has distinct transcriptional regulation. Methods: The expression of cyclin D3 was compared in E sensitive cell lines (H358, H441) and an E resistant cell line (A549). Cyclins D1, D2, and D3 were independently overexpressed in E sensitive NIH 3T3 cells by plasmid transfection. Biopsy tissues from a proof-of-principal clinical trial of E were assessed for cyclin D3 expression. Results: A549 cells were resistant to E and expressed high levels of cyclin D3 RNA and protein compared to E sensitive cell lines. Overexpression of cyclin D1 and cyclin D3 conferred partial resistance to E in NIH 3T3 cells while cyclin D2 had no significant effect. Comparison of cyclin D3 immunostaining in tumor biopsies from patients before and after treatment with E revealed an increase in the percentage of cyclin D3 expressing cells following treatment with E. Conclusions: Cyclin D3 confers resistance to E in vitro and in vivo. Drugs such as retinoids and rexinoids that target cyclin D3 expression may prove useful for enhancing sensitivity to E. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- W. J. Petty
- Wake Forest Univ School of Medcn, Winston Salem, NC; Dartmouth Medical School, Hanover, NH
| | - W. R. Voelzke
- Wake Forest Univ School of Medcn, Winston Salem, NC; Dartmouth Medical School, Hanover, NH
| | - V. A. Memoli
- Wake Forest Univ School of Medcn, Winston Salem, NC; Dartmouth Medical School, Hanover, NH
| | - K. H. Dragnev
- Wake Forest Univ School of Medcn, Winston Salem, NC; Dartmouth Medical School, Hanover, NH
| | - J. J. Urbanic
- Wake Forest Univ School of Medcn, Winston Salem, NC; Dartmouth Medical School, Hanover, NH
| | - J. R. Rigas
- Wake Forest Univ School of Medcn, Winston Salem, NC; Dartmouth Medical School, Hanover, NH
| | - E. Dmitrovsky
- Wake Forest Univ School of Medcn, Winston Salem, NC; Dartmouth Medical School, Hanover, NH
| |
Collapse
|
16
|
Dragnev KH, Rigas JR, Disalvo WM, Simeone SA, Hagey AE, Gordon GB, Dmitrovsky E. A phase I trial of ABT-751 and carboplatin (C) in patients (pts) with previously treated non-small cell lung cancer (NSCLC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.17098] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
17098 Background: NSCLC is the leading cause of cancer mortality for men and women in the United States. More effective treatments are needed to prolong survival and improve quality of life. Platin-containing chemotherapy doublets are commonly used in NSCLC treatment. ABT-751 is a novel oral anti-microtubule agent targeting the colchicine binding site. As single agent, it was well-tolerated and showed a preliminary signal of activity in previously treated NSCLC. In vivo studies demonstrated additive activity between ABT-751 and cisplatin in a NSCLC xenograft model. Methods: A phase I trial of ABT-751 and C was conducted in pts with advanced previously treated NSCLC. Primary objective - maximum tolerated dose (MTD). Secondary objectives - toxicities, efficacy, and surrogate markers of response (cell cycle changes and cyclin D1 expression) in buccal swabs from pts at the phase II dose. Six dose levels - 1: ABT-751 100mg bid, C AUC 4.5; 2: ABT-751 125 mg bid, C AUC 4.5; 3: ABT-751 125 mg bid, C AUC 6; 4: ABT-751 150 mg bid, C AUC 6; 5: ABT-751 175 mg bid, C AUC 6; 6: ABT-751 200 mg bid, C AUC 6. ABT-751 was taken orally twice a day for 14 days in a 21 day cycle, C was administered intravenously on day 4 during cycle 1 and on day 1 on subsequent cycles. Rapid dose escalation was used for the first 3 dose levels followed by cohorts of at least 3 patients for the remaining dose levels. Results: Eight pts were enrolled, all stage IV NSCLC, 4 women, median age 62 (47–73), all KPS 80, 6 had one and 2 had 2 prior therapies. A median of 3.5 (1–4) cycles was administered. Dose-limiting toxiticies of grade 3 fatigue and grade 4 thrombocytopenia and neutropenia were observed in 2/5 patients on dose level 4. Common grade 2 toxicites were constipation and peripheral sensory neuropathy (levels 2–4). MTD was dose level 3. Seven pts were evaluable for response, 2 had partial responses (levels 2 and 4, both had one prior therapy), 4 had stable disease, 1 had disease progression. Median time to progression was 18.7 weeks (6–24+). Pharmacokinetic analyses and buccal swabs are being performed. Conclusions: The recommended phase II doses are ABT-751 125 mg twice daily for 14 days and carboplatin AUC 6 on a 21-day cycle. This regimen is well tolerated and shows preliminary evidence of activity for previously treated NSCLC. [Table: see text]
Collapse
Affiliation(s)
- K. H. Dragnev
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; Abbott Laboratories, Abbott Park, IL; Dartmouth Medical School, Hanover, NH
| | - J. R. Rigas
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; Abbott Laboratories, Abbott Park, IL; Dartmouth Medical School, Hanover, NH
| | - W. M. Disalvo
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; Abbott Laboratories, Abbott Park, IL; Dartmouth Medical School, Hanover, NH
| | - S. A. Simeone
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; Abbott Laboratories, Abbott Park, IL; Dartmouth Medical School, Hanover, NH
| | - A. E. Hagey
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; Abbott Laboratories, Abbott Park, IL; Dartmouth Medical School, Hanover, NH
| | - G. B. Gordon
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; Abbott Laboratories, Abbott Park, IL; Dartmouth Medical School, Hanover, NH
| | - E. Dmitrovsky
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; Abbott Laboratories, Abbott Park, IL; Dartmouth Medical School, Hanover, NH
| |
Collapse
|
17
|
Gauthier I, Ding K, Winton T, Shepherd F, Livingston R, Johnson DH, Rigas JR, Whitehead M, Graham B, Seymour L. Impact of hemoglobin (Hb) on outcomes of adjuvant chemotherapy (ACT) with cisplatin/vinorelbine in patients (pts) with completely resected non-small cell lung cancer (NSCLC) in JBR.10. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- I. Gauthier
- National Cancer Institute of Canada, Kingston, ON, Canada; Southwest Oncology Group, Seattle, WA; Eastern Cooperative Oncology Group, Nashville, TN; Cancer and Leukemia Group B, Chicago, IL
| | - K. Ding
- National Cancer Institute of Canada, Kingston, ON, Canada; Southwest Oncology Group, Seattle, WA; Eastern Cooperative Oncology Group, Nashville, TN; Cancer and Leukemia Group B, Chicago, IL
| | - T. Winton
- National Cancer Institute of Canada, Kingston, ON, Canada; Southwest Oncology Group, Seattle, WA; Eastern Cooperative Oncology Group, Nashville, TN; Cancer and Leukemia Group B, Chicago, IL
| | - F. Shepherd
- National Cancer Institute of Canada, Kingston, ON, Canada; Southwest Oncology Group, Seattle, WA; Eastern Cooperative Oncology Group, Nashville, TN; Cancer and Leukemia Group B, Chicago, IL
| | - R. Livingston
- National Cancer Institute of Canada, Kingston, ON, Canada; Southwest Oncology Group, Seattle, WA; Eastern Cooperative Oncology Group, Nashville, TN; Cancer and Leukemia Group B, Chicago, IL
| | - D. H. Johnson
- National Cancer Institute of Canada, Kingston, ON, Canada; Southwest Oncology Group, Seattle, WA; Eastern Cooperative Oncology Group, Nashville, TN; Cancer and Leukemia Group B, Chicago, IL
| | - J. R. Rigas
- National Cancer Institute of Canada, Kingston, ON, Canada; Southwest Oncology Group, Seattle, WA; Eastern Cooperative Oncology Group, Nashville, TN; Cancer and Leukemia Group B, Chicago, IL
| | - M. Whitehead
- National Cancer Institute of Canada, Kingston, ON, Canada; Southwest Oncology Group, Seattle, WA; Eastern Cooperative Oncology Group, Nashville, TN; Cancer and Leukemia Group B, Chicago, IL
| | - B. Graham
- National Cancer Institute of Canada, Kingston, ON, Canada; Southwest Oncology Group, Seattle, WA; Eastern Cooperative Oncology Group, Nashville, TN; Cancer and Leukemia Group B, Chicago, IL
| | - L. Seymour
- National Cancer Institute of Canada, Kingston, ON, Canada; Southwest Oncology Group, Seattle, WA; Eastern Cooperative Oncology Group, Nashville, TN; Cancer and Leukemia Group B, Chicago, IL
| |
Collapse
|
18
|
Hermann T, Dragnev KH, Rigas JR, Petty WJ, Dmitrovsky E, Negro-Vilar A, Lamph W. Microarray gene expression analysis reveals molecular activities of bexarotene in in vitro models of non-dmall vell lung cancer (NSCLC) and in tumors of NSCLC patients. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7234] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- T. Hermann
- Ligand Pharmaceuticals, San Diego, CA; Dartmouth Medcl Sch, Hanover, NH
| | - K. H. Dragnev
- Ligand Pharmaceuticals, San Diego, CA; Dartmouth Medcl Sch, Hanover, NH
| | - J. R. Rigas
- Ligand Pharmaceuticals, San Diego, CA; Dartmouth Medcl Sch, Hanover, NH
| | - W. J. Petty
- Ligand Pharmaceuticals, San Diego, CA; Dartmouth Medcl Sch, Hanover, NH
| | - E. Dmitrovsky
- Ligand Pharmaceuticals, San Diego, CA; Dartmouth Medcl Sch, Hanover, NH
| | - A. Negro-Vilar
- Ligand Pharmaceuticals, San Diego, CA; Dartmouth Medcl Sch, Hanover, NH
| | - W. Lamph
- Ligand Pharmaceuticals, San Diego, CA; Dartmouth Medcl Sch, Hanover, NH
| |
Collapse
|
19
|
Petty WJ, Dragnev KH, Black WC, Cole BF, Hammond S, Williams I, Dmitrovsky E, Rigas JR. Weekly paclitaxel, carboplatin, and bexarotene for the treatment of patients with advanced non-small cell lung cancer: Efficacy results from a phase I/II study. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- W. J. Petty
- Dartmouth Medcl Sch, Hanover, NH; Dartmouth-Hitchcock Medcl Ctr, Lebanon, NH
| | - K. H. Dragnev
- Dartmouth Medcl Sch, Hanover, NH; Dartmouth-Hitchcock Medcl Ctr, Lebanon, NH
| | - W. C. Black
- Dartmouth Medcl Sch, Hanover, NH; Dartmouth-Hitchcock Medcl Ctr, Lebanon, NH
| | - B. F. Cole
- Dartmouth Medcl Sch, Hanover, NH; Dartmouth-Hitchcock Medcl Ctr, Lebanon, NH
| | - S. Hammond
- Dartmouth Medcl Sch, Hanover, NH; Dartmouth-Hitchcock Medcl Ctr, Lebanon, NH
| | - I. Williams
- Dartmouth Medcl Sch, Hanover, NH; Dartmouth-Hitchcock Medcl Ctr, Lebanon, NH
| | - E. Dmitrovsky
- Dartmouth Medcl Sch, Hanover, NH; Dartmouth-Hitchcock Medcl Ctr, Lebanon, NH
| | - J. R. Rigas
- Dartmouth Medcl Sch, Hanover, NH; Dartmouth-Hitchcock Medcl Ctr, Lebanon, NH
| |
Collapse
|
20
|
Blumenschein GR, Khuri F, Gatzemeier U, Miller WH, von Pawel J, Rigas JR, Herbst RS, Dziewanowska Z, Negro-Vilar A, Mabry M. A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.lba7001] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- G. R. Blumenschein
- UT M.D. Anderson Cancer Ctr, Houston, TX; Winship Cancer Institute, Emory Univ, Atlanta, GA; Hosp Grosshansdorf, Grosshansdorf, Germany; McGill Univ, Montreal, PQ, Canada; Asklepios Fachklinken Munchen Gauting, Munich, Germany; Dartmouth Medcl Sch, Lebanon, NH; Ligand Pharmaceuticals, San Diego, CA
| | - F. Khuri
- UT M.D. Anderson Cancer Ctr, Houston, TX; Winship Cancer Institute, Emory Univ, Atlanta, GA; Hosp Grosshansdorf, Grosshansdorf, Germany; McGill Univ, Montreal, PQ, Canada; Asklepios Fachklinken Munchen Gauting, Munich, Germany; Dartmouth Medcl Sch, Lebanon, NH; Ligand Pharmaceuticals, San Diego, CA
| | - U. Gatzemeier
- UT M.D. Anderson Cancer Ctr, Houston, TX; Winship Cancer Institute, Emory Univ, Atlanta, GA; Hosp Grosshansdorf, Grosshansdorf, Germany; McGill Univ, Montreal, PQ, Canada; Asklepios Fachklinken Munchen Gauting, Munich, Germany; Dartmouth Medcl Sch, Lebanon, NH; Ligand Pharmaceuticals, San Diego, CA
| | - W. H. Miller
- UT M.D. Anderson Cancer Ctr, Houston, TX; Winship Cancer Institute, Emory Univ, Atlanta, GA; Hosp Grosshansdorf, Grosshansdorf, Germany; McGill Univ, Montreal, PQ, Canada; Asklepios Fachklinken Munchen Gauting, Munich, Germany; Dartmouth Medcl Sch, Lebanon, NH; Ligand Pharmaceuticals, San Diego, CA
| | - J. von Pawel
- UT M.D. Anderson Cancer Ctr, Houston, TX; Winship Cancer Institute, Emory Univ, Atlanta, GA; Hosp Grosshansdorf, Grosshansdorf, Germany; McGill Univ, Montreal, PQ, Canada; Asklepios Fachklinken Munchen Gauting, Munich, Germany; Dartmouth Medcl Sch, Lebanon, NH; Ligand Pharmaceuticals, San Diego, CA
| | - J. R. Rigas
- UT M.D. Anderson Cancer Ctr, Houston, TX; Winship Cancer Institute, Emory Univ, Atlanta, GA; Hosp Grosshansdorf, Grosshansdorf, Germany; McGill Univ, Montreal, PQ, Canada; Asklepios Fachklinken Munchen Gauting, Munich, Germany; Dartmouth Medcl Sch, Lebanon, NH; Ligand Pharmaceuticals, San Diego, CA
| | - R. S. Herbst
- UT M.D. Anderson Cancer Ctr, Houston, TX; Winship Cancer Institute, Emory Univ, Atlanta, GA; Hosp Grosshansdorf, Grosshansdorf, Germany; McGill Univ, Montreal, PQ, Canada; Asklepios Fachklinken Munchen Gauting, Munich, Germany; Dartmouth Medcl Sch, Lebanon, NH; Ligand Pharmaceuticals, San Diego, CA
| | - Z. Dziewanowska
- UT M.D. Anderson Cancer Ctr, Houston, TX; Winship Cancer Institute, Emory Univ, Atlanta, GA; Hosp Grosshansdorf, Grosshansdorf, Germany; McGill Univ, Montreal, PQ, Canada; Asklepios Fachklinken Munchen Gauting, Munich, Germany; Dartmouth Medcl Sch, Lebanon, NH; Ligand Pharmaceuticals, San Diego, CA
| | - A. Negro-Vilar
- UT M.D. Anderson Cancer Ctr, Houston, TX; Winship Cancer Institute, Emory Univ, Atlanta, GA; Hosp Grosshansdorf, Grosshansdorf, Germany; McGill Univ, Montreal, PQ, Canada; Asklepios Fachklinken Munchen Gauting, Munich, Germany; Dartmouth Medcl Sch, Lebanon, NH; Ligand Pharmaceuticals, San Diego, CA
| | - M. Mabry
- UT M.D. Anderson Cancer Ctr, Houston, TX; Winship Cancer Institute, Emory Univ, Atlanta, GA; Hosp Grosshansdorf, Grosshansdorf, Germany; McGill Univ, Montreal, PQ, Canada; Asklepios Fachklinken Munchen Gauting, Munich, Germany; Dartmouth Medcl Sch, Lebanon, NH; Ligand Pharmaceuticals, San Diego, CA
| |
Collapse
|
21
|
Rigas JR, Dragnev KH, Petty WJ, Nugent WC, Memoli VA, Black CC, Lewis LD, Loewen G, Negro-Vilar A, Dmitrovsky E. A proof-of-principle trial of bexarotene in patients (pts) with resectable non-small cell lung cancer (NSCLC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. R. Rigas
- Dartmouth Medcl Sch, Lebanon, NH; Ligand pharmaceuticals, Inc, San Diego, CA
| | - K. H. Dragnev
- Dartmouth Medcl Sch, Lebanon, NH; Ligand pharmaceuticals, Inc, San Diego, CA
| | - W. J. Petty
- Dartmouth Medcl Sch, Lebanon, NH; Ligand pharmaceuticals, Inc, San Diego, CA
| | - W. C. Nugent
- Dartmouth Medcl Sch, Lebanon, NH; Ligand pharmaceuticals, Inc, San Diego, CA
| | - V. A. Memoli
- Dartmouth Medcl Sch, Lebanon, NH; Ligand pharmaceuticals, Inc, San Diego, CA
| | - C. C. Black
- Dartmouth Medcl Sch, Lebanon, NH; Ligand pharmaceuticals, Inc, San Diego, CA
| | - L. D. Lewis
- Dartmouth Medcl Sch, Lebanon, NH; Ligand pharmaceuticals, Inc, San Diego, CA
| | - G. Loewen
- Dartmouth Medcl Sch, Lebanon, NH; Ligand pharmaceuticals, Inc, San Diego, CA
| | - A. Negro-Vilar
- Dartmouth Medcl Sch, Lebanon, NH; Ligand pharmaceuticals, Inc, San Diego, CA
| | - E. Dmitrovsky
- Dartmouth Medcl Sch, Lebanon, NH; Ligand pharmaceuticals, Inc, San Diego, CA
| |
Collapse
|
22
|
Dragnev KH, Petty WJ, Shah S, Carey MA, Disalvo WM, Williams I, Rigas JR, Dmitrovsky E. A phase I trial of erlotinib and bexarotene as a targeted combination therapy for aerodigestive tract cancers. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. H. Dragnev
- Dartmouth-Hitchcock Medcl Ctr, Lebanon, NH; Dartmouth Medcl Sch, Hanover, NH
| | - W. J. Petty
- Dartmouth-Hitchcock Medcl Ctr, Lebanon, NH; Dartmouth Medcl Sch, Hanover, NH
| | - S. Shah
- Dartmouth-Hitchcock Medcl Ctr, Lebanon, NH; Dartmouth Medcl Sch, Hanover, NH
| | - M. A. Carey
- Dartmouth-Hitchcock Medcl Ctr, Lebanon, NH; Dartmouth Medcl Sch, Hanover, NH
| | - W. M. Disalvo
- Dartmouth-Hitchcock Medcl Ctr, Lebanon, NH; Dartmouth Medcl Sch, Hanover, NH
| | - I. Williams
- Dartmouth-Hitchcock Medcl Ctr, Lebanon, NH; Dartmouth Medcl Sch, Hanover, NH
| | - J. R. Rigas
- Dartmouth-Hitchcock Medcl Ctr, Lebanon, NH; Dartmouth Medcl Sch, Hanover, NH
| | - E. Dmitrovsky
- Dartmouth-Hitchcock Medcl Ctr, Lebanon, NH; Dartmouth Medcl Sch, Hanover, NH
| |
Collapse
|
23
|
Ross HJ, Blumenschein GR, Dowlati A, Aisner J, Rigas JR, Stanislaus M, Leopold LH. Preliminary safety results of a phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7099] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- H. J. Ross
- Earle A. Chiles Research Institute, Portland, OR; UT M. D. Anderson Cancer Ctr, Houston, TX; Case Western Reserve Univ, Cleveland, OH; The Cancer Institute of New Jersey, New Brunswick, NJ; Dartmouth Medcl Sch, Lebanon, NH; GlaxoSmithKline, Collegeville, PA; GlaxoSmithKline, Philadelphia, PA
| | - G. R. Blumenschein
- Earle A. Chiles Research Institute, Portland, OR; UT M. D. Anderson Cancer Ctr, Houston, TX; Case Western Reserve Univ, Cleveland, OH; The Cancer Institute of New Jersey, New Brunswick, NJ; Dartmouth Medcl Sch, Lebanon, NH; GlaxoSmithKline, Collegeville, PA; GlaxoSmithKline, Philadelphia, PA
| | - A. Dowlati
- Earle A. Chiles Research Institute, Portland, OR; UT M. D. Anderson Cancer Ctr, Houston, TX; Case Western Reserve Univ, Cleveland, OH; The Cancer Institute of New Jersey, New Brunswick, NJ; Dartmouth Medcl Sch, Lebanon, NH; GlaxoSmithKline, Collegeville, PA; GlaxoSmithKline, Philadelphia, PA
| | - J. Aisner
- Earle A. Chiles Research Institute, Portland, OR; UT M. D. Anderson Cancer Ctr, Houston, TX; Case Western Reserve Univ, Cleveland, OH; The Cancer Institute of New Jersey, New Brunswick, NJ; Dartmouth Medcl Sch, Lebanon, NH; GlaxoSmithKline, Collegeville, PA; GlaxoSmithKline, Philadelphia, PA
| | - J. R. Rigas
- Earle A. Chiles Research Institute, Portland, OR; UT M. D. Anderson Cancer Ctr, Houston, TX; Case Western Reserve Univ, Cleveland, OH; The Cancer Institute of New Jersey, New Brunswick, NJ; Dartmouth Medcl Sch, Lebanon, NH; GlaxoSmithKline, Collegeville, PA; GlaxoSmithKline, Philadelphia, PA
| | - M. Stanislaus
- Earle A. Chiles Research Institute, Portland, OR; UT M. D. Anderson Cancer Ctr, Houston, TX; Case Western Reserve Univ, Cleveland, OH; The Cancer Institute of New Jersey, New Brunswick, NJ; Dartmouth Medcl Sch, Lebanon, NH; GlaxoSmithKline, Collegeville, PA; GlaxoSmithKline, Philadelphia, PA
| | - L. H. Leopold
- Earle A. Chiles Research Institute, Portland, OR; UT M. D. Anderson Cancer Ctr, Houston, TX; Case Western Reserve Univ, Cleveland, OH; The Cancer Institute of New Jersey, New Brunswick, NJ; Dartmouth Medcl Sch, Lebanon, NH; GlaxoSmithKline, Collegeville, PA; GlaxoSmithKline, Philadelphia, PA
| |
Collapse
|
24
|
Rigas JR, Carey M, Cole B, Evans A, Page R, Yunus F, Ruben M, Ghazal H, Dragnev K. Multicenter Web-based phase III study to test the survival equivalence of non-platinum-based (NPB) vs platinum-based (PB) therapy for advanced non-small cell lung cancer (NSCLC): The Dartmouth NPB Chemotherapy Trial (D0112). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. R. Rigas
- Dartmouth Medical School, Hanover, NH; Norris Cotton Cancer Center, Lebanon, NH; PPD Development, Wilmington, NC; Texas Cancer Care, Fort Worth, TX; University of Tennessee, Memphis, TN; Florida Cancer Specialist, Bonita Springs, FL; Appalachian Clinical Research, Pikeville, KY; Dartmouth Hitchcock Medical Center, Lebanon, NH
| | - M. Carey
- Dartmouth Medical School, Hanover, NH; Norris Cotton Cancer Center, Lebanon, NH; PPD Development, Wilmington, NC; Texas Cancer Care, Fort Worth, TX; University of Tennessee, Memphis, TN; Florida Cancer Specialist, Bonita Springs, FL; Appalachian Clinical Research, Pikeville, KY; Dartmouth Hitchcock Medical Center, Lebanon, NH
| | - B. Cole
- Dartmouth Medical School, Hanover, NH; Norris Cotton Cancer Center, Lebanon, NH; PPD Development, Wilmington, NC; Texas Cancer Care, Fort Worth, TX; University of Tennessee, Memphis, TN; Florida Cancer Specialist, Bonita Springs, FL; Appalachian Clinical Research, Pikeville, KY; Dartmouth Hitchcock Medical Center, Lebanon, NH
| | - A. Evans
- Dartmouth Medical School, Hanover, NH; Norris Cotton Cancer Center, Lebanon, NH; PPD Development, Wilmington, NC; Texas Cancer Care, Fort Worth, TX; University of Tennessee, Memphis, TN; Florida Cancer Specialist, Bonita Springs, FL; Appalachian Clinical Research, Pikeville, KY; Dartmouth Hitchcock Medical Center, Lebanon, NH
| | - R. Page
- Dartmouth Medical School, Hanover, NH; Norris Cotton Cancer Center, Lebanon, NH; PPD Development, Wilmington, NC; Texas Cancer Care, Fort Worth, TX; University of Tennessee, Memphis, TN; Florida Cancer Specialist, Bonita Springs, FL; Appalachian Clinical Research, Pikeville, KY; Dartmouth Hitchcock Medical Center, Lebanon, NH
| | - F. Yunus
- Dartmouth Medical School, Hanover, NH; Norris Cotton Cancer Center, Lebanon, NH; PPD Development, Wilmington, NC; Texas Cancer Care, Fort Worth, TX; University of Tennessee, Memphis, TN; Florida Cancer Specialist, Bonita Springs, FL; Appalachian Clinical Research, Pikeville, KY; Dartmouth Hitchcock Medical Center, Lebanon, NH
| | - M. Ruben
- Dartmouth Medical School, Hanover, NH; Norris Cotton Cancer Center, Lebanon, NH; PPD Development, Wilmington, NC; Texas Cancer Care, Fort Worth, TX; University of Tennessee, Memphis, TN; Florida Cancer Specialist, Bonita Springs, FL; Appalachian Clinical Research, Pikeville, KY; Dartmouth Hitchcock Medical Center, Lebanon, NH
| | - H. Ghazal
- Dartmouth Medical School, Hanover, NH; Norris Cotton Cancer Center, Lebanon, NH; PPD Development, Wilmington, NC; Texas Cancer Care, Fort Worth, TX; University of Tennessee, Memphis, TN; Florida Cancer Specialist, Bonita Springs, FL; Appalachian Clinical Research, Pikeville, KY; Dartmouth Hitchcock Medical Center, Lebanon, NH
| | - K. Dragnev
- Dartmouth Medical School, Hanover, NH; Norris Cotton Cancer Center, Lebanon, NH; PPD Development, Wilmington, NC; Texas Cancer Care, Fort Worth, TX; University of Tennessee, Memphis, TN; Florida Cancer Specialist, Bonita Springs, FL; Appalachian Clinical Research, Pikeville, KY; Dartmouth Hitchcock Medical Center, Lebanon, NH
| |
Collapse
|
25
|
Bubis JA, Williams I, Dragnev KH, Sutton JE, Gordon SR, Zaki BI, Cole BF, Rigas JR. Docetaxel (DTX) and carboplatin (CP) followed by a dose-ranging study of oral capecitabine, weekly DTX, concomitant radiotherapy and surgery for the treatment of patients with stage II-III carcinoma of the esophagus. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. A. Bubis
- Dartmouth-Hitchcock Medical Center, Lebanon, NH
| | - I. Williams
- Dartmouth-Hitchcock Medical Center, Lebanon, NH
| | | | | | | | - B. I. Zaki
- Dartmouth-Hitchcock Medical Center, Lebanon, NH
| | - B. F. Cole
- Dartmouth-Hitchcock Medical Center, Lebanon, NH
| | - J. R. Rigas
- Dartmouth-Hitchcock Medical Center, Lebanon, NH
| |
Collapse
|
26
|
Petty WJ, Dragnev KH, Memoli VA, Davis TH, Nugent WC, Williams IR, Iwata KK, Hamilton M, Rigas JR, Dmitrovsky E. Cyclin D1 repression as a marker of erlotinib response in aerodigestive tract cancers. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- W. J. Petty
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; OSI Pharmaceuticals, Melville, NY
| | - K. H. Dragnev
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; OSI Pharmaceuticals, Melville, NY
| | - V. A. Memoli
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; OSI Pharmaceuticals, Melville, NY
| | - T. H. Davis
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; OSI Pharmaceuticals, Melville, NY
| | - W. C. Nugent
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; OSI Pharmaceuticals, Melville, NY
| | - I. R. Williams
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; OSI Pharmaceuticals, Melville, NY
| | - K. K. Iwata
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; OSI Pharmaceuticals, Melville, NY
| | - M. Hamilton
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; OSI Pharmaceuticals, Melville, NY
| | - J. R. Rigas
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; OSI Pharmaceuticals, Melville, NY
| | - E. Dmitrovsky
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; OSI Pharmaceuticals, Melville, NY
| |
Collapse
|
27
|
Dragnev KH, Petty WJ, Memoli V, Black W, Williams I, Rigas JR, Dmitrovsky E. A phase I/II study of bexarotene (B) and erlotinib (E): A novel targeted combination therapy for lung cancer and other aerodigestive tract (ADT) tumors. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3092] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. H. Dragnev
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; Dartmouth Medical School, Hanover, NH
| | - W. J. Petty
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; Dartmouth Medical School, Hanover, NH
| | - V. Memoli
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; Dartmouth Medical School, Hanover, NH
| | - W. Black
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; Dartmouth Medical School, Hanover, NH
| | - I. Williams
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; Dartmouth Medical School, Hanover, NH
| | - J. R. Rigas
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; Dartmouth Medical School, Hanover, NH
| | - E. Dmitrovsky
- Dartmouth-Hitchcock Medical Center, Lebanon, NH; Dartmouth Medical School, Hanover, NH
| |
Collapse
|
28
|
Rigas JR. Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan. Semin Oncol 2001; 28:15-20. [PMID: 11441410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
Non-platinum combination regimens have been developed for advanced non--small cell lung cancer using the novel and active agents docetaxel, gemcitabine, vinorelbine, and irinotecan. The aim of these combinations is to equal or exceed the survival benefits achieved with cisplatin doublets while minimizing toxicity. Of the docetaxel-based combinations, gemcitabine has been the most extensively studied. In a 317-patient randomized trial, docetaxel plus gemcitabine achieved a response rate of 34%, similar to the 32% response rate seen in patients randomized to docetaxel plus cisplatin. One-year survival rates were 38% and 42%, respectively. While being equally active, the docetaxel/gemcitabine combination was associated with significantly less neutropenia and gastrointestinal adverse events than the cisplatin-containing regimen. Phase II trials of docetaxel plus vinorelbine have reported response rates of up to 51% and 1-year survival in up to 60% of patients without significant peripheral neuropathy. Docetaxel plus irinotecan is also active in advanced non--small cell lung cancer and has shown similar efficacy to docetaxel plus cisplatin in a randomized trial. The adverse event profile of docetaxel/irinotecan is different from that of cisplatin-based regimens. Both non-platinum and platinum combination regimens have an important role to play in the treatment of non--small cell lung cancer. Semin Oncol 28 (suppl 9):15-20.
Collapse
Affiliation(s)
- J R Rigas
- Department of Medicine, Section of Hematology/Oncology Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
| |
Collapse
|
29
|
Khuri FR, Rigas JR, Figlin RA, Gralla RJ, Shin DM, Munden R, Fox N, Huyghe MR, Kean Y, Reich SD, Hong WK. Multi-Institutional Phase I/II Trial of Oral Bexarotene in Combination With Cisplatin and Vinorelbine in Previously Untreated Patients With Advanced Non–Small-Cell Lung Cancer. J Clin Oncol 2001; 19:2626-37. [PMID: 11352954 DOI: 10.1200/jco.2001.19.10.2626] [Citation(s) in RCA: 96] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE: Bexarotene (Targretin; Ligand Pharmaceuticals, Inc, San Diego, CA) is a retinoid-X-receptor (RXR)-selective retinoid with preclinical antitumor activity in squamous cell cancers. In this phase I/II trial, we combined bexarotene with cisplatin and vinorelbine in the treatment of patients with non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Forty-three patients who had stage IIIB NSCLC with pleural effusion or stage IV NSCLC and had received no prior therapy received bexarotene in combination with cisplatin (100 mg/m2) and vinorelbine (alternating doses of 30 mg/m2 and 15 mg/m2). In the phase I portion, the daily dose of bexarotene was escalated in cohorts of three patients from 150 mg/m2 to 600 mg/m2, beginning 1 week before the start of the cisplatin-vinorelbine regimen. Once the maximum-tolerated dose (MTD) of bexarotene was determined, the study entered the phase II portion. Response rate was the primary end point; median survival time and 1-year survival rate were secondary end points. RESULTS: In the phase I portion, the daily MTD of bexarotene was determined to be 400 mg/m2. Eight of 43 patients exhibited major responses. Seven (25%) of the 28 patients in the phase II portion responded to treatment. The median survival time in the phase II portion was 14 months; nine (32%) of the 28 patients were still alive at a minimum follow-up of 2 years. One-year and projected 3-year survival rates were 61% and 30%, respectively. The most common grade 3 and 4 adverse events were hyperlipemia, leukopenia, nausea, vomiting, pneumonia, dyspnea, anemia, and asthenia. Grade 3 and 4 laboratory abnormalities with incidences greater than 5% were decreased hemoglobin levels and WBC, absolute neutrophil, and absolute lymphocyte counts and increased prothrombin time and creatinine and amylase levels. Of the two cases of pancreatitis, one required hospitalization and both were associated with increased triglyceride levels. There was one death secondary to renal insufficiency unrelated to bexarotene treatment. CONCLUSION: In patients with advanced NSCLC, bexarotene with cisplatin and vinorelbine yielded acceptable phase II response rates (25%) and was associated with better-than-expected survival (14-month median survival time; 61% 1-year, 32% 2-year, and 30% projected 3-year survival rates). The regimen should be studied in larger clinical trials.
Collapse
Affiliation(s)
- F R Khuri
- Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Abstract
Carcinogenesis is a multistep process that converts normal cells into malignant cells. Once transformed, malignant cells acquire the ability to invade and metastasize, leading to clinically evident disease. During this continuum from normal to metastatic cells, carcinogenic steps can be arrested or reversed through pharmacological treatments, known as cancer chemoprevention. Chemoprevention strategies represent therapeutic interventions at early stages of carcinogenesis, before the onset of invasive cancer. Effective chemoprevention should reduce or avoid the clinical consequences of overt malignancies by treating early neoplastic lesions before development of clinically apparent signs or symptoms. Preclinical, clinical, and epidemiological data provide considerable support for cancer chemoprevention as an attractive therapeutic strategy. This clinical approach was validated in the recent tamoxifen randomized trial, demonstrating that a selective estrogen receptor modulator reduces the risk of breast cancer in women at high risk for this malignancy. Derivatives of vitamin A, the retinoids, have reported activity in treating specific premalignant lesions and reducing incidence of second primary tumors in patients with prior head and neck, lung or liver cancers. Whether the retinoids will prevent primary cancers at these sites is not yet known. Notably, a carotenoid (beta-carotene) was shown as inactive in primary prevention of lung cancers in high-risk individuals. This underscores the need for relevant in vitro models to identify pathways signaling chemopreventive effects. These models should assess the activity of candidate chemoprevention agents before the conduct of large and costly prevention trials. An improved understanding of cancer prevention mechanisms should aid in the discovery of new therapeutic targets and chemoprevention agents. Ideally, these agents should have tolerable clinical toxicities suitable for chronic administration to individuals at high risk for developing primary or second cancers. This article reviews what is now known from clinical and preclinical studies about the retinoids as cancer prevention agents.
Collapse
Affiliation(s)
- K H Dragnev
- The Norris Cotton Cancer Center and Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
| | | | | |
Collapse
|
31
|
Shepherd FA, Fossella FV, Lynch T, Armand JP, Rigas JR, Kris MG. Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials. Semin Oncol 2001; 28:4-9. [PMID: 11284623 DOI: 10.1016/s0093-7754(01)90297-0] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The potential benefits of docetaxel (Taxotere; Aventis, Antony, France) to patients with previously-treated non-small cell lung cancer have been evaluated in two prospective randomized phase III trials. In one study, patients with stage IIIB/IV non-small cell lung cancer who had failed previous cisplatin-based chemotherapy were randomized to receive either docetaxel (100 or 75 mg/m2, once every 3 weeks) or best supportive care. Median survival was significantly longer for patients treated with docetaxel 75 mg/m2 (7.5 months v 4.6 months) as was 1-year survival (37% v 11%). A second trial, also in platinum-pretreated patients, randomized patients to docetaxel 100 mg/m2, docetaxel 75 mg/m2, or vinorelbine/ifosfamide. Median survival was similar across the three study groups. Thirty-two percent of patients assigned to docetaxel 75 mg/m2 and 21% to docetaxel 100 mg/m2, were alive at 1 year, versus 19% on the vinorelbine/ifosfamide arm. Docetaxel offers clinically meaningful benefits in the second-line setting. The recommended dose is 75 mg/m2 once every 3 weeks. The adverse events observed were predictable, tolerable, and manageable. These phase III trials showed that docetaxel provided clinical benefits to patients with non-small cell lung cancer.
Collapse
Affiliation(s)
- F A Shepherd
- Princess Margaret Hospital, University of Toronto, Ontario, Canada
| | | | | | | | | | | |
Collapse
|
32
|
Balestrero LM, Beaver CR, Rigas JR. Hypertensive crisis following meperidine administration and chemoembolization of a carcinoid tumor. Arch Intern Med 2000; 160:2394-5. [PMID: 10927742 DOI: 10.1001/archinte.160.15.2394-a] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
33
|
Abstract
Anticancer treatment has recently shifted to include a broad range of antineoplastic therapies. Old agents are continuously being re-evaluated, and new mechanisms of treatment are rapidly being explored and developed. At the same time, the patient's perceived quality of life, adverse effects of therapy, time demands, and healthcare costs have become paramount in the treatment process. Lung cancer is the most common cause of cancer death in the USA, and because many of the patients are older or debilitated, these issues become all the more important. The oral administration of anticancer therapy offers both quality-of-life and healthcare cost advantages. Oral forms of 3 new cytotoxic agents and 2 novel oral therapies are discussed. Vinorelbine, a vinca alkaloid, has well documented activity in non-small cell lung cancer. Myelosuppression is dose limiting; neurotoxicity is rare. Satraplatin (JM-216), an oral platinum derivative, shows activity in lung cancer with a favourable adverse effect profile, with no neurotoxicity or nephrotoxicity. The oral topoisomerase I inhibitor topotecan may be ideal for obtaining long term low plasma drug concentrations, which appears to maximise efficacy. LGD-1069 is a retinoid X receptor agonist that modulates cell proliferation, and BAY-129566, a matrix metalloproteinase inhibitor, appears to interrupt both the processes of angiogenesis and metastasis. LGD-1069 and BAY-129566 are nontraditional anticancer agents which may be used in conjunction with chemotherapy, other modalities, or in prevention. These 5 agents will be discussed with particular reference to recent developments in the treatment of lung cancer.
Collapse
Affiliation(s)
- E M Bengtson
- Dartmouth Medical School, Hanover, New Hampshire, USA
| | | |
Collapse
|
34
|
Abstract
The 1990s have introduced a number of novel chemotherapeutic agents with activity in non small-cell lung carcinoma. Docetaxel and gemcitabine appear to be two of the most active new agents. Their use in non small-cell lung carcinoma has been associated with improvements in survival, palliation of symptoms, and maintenance of quality of life when compared to best supportive care. Options for treatment of non small-cell lung carcinoma after platinum have been limited. These newer agents have substantial activity in this subset of patients. This review focuses on the current data using the combination of docetaxel and gemcitabine in the fight against non small-cell lung carcinoma.
Collapse
Affiliation(s)
- A J Olszanski
- Thoracic Oncology Program, Norris Cotton Cancer Center, One Medical Center Drive, Lebanon, NH 03756-0001, USA
| | | |
Collapse
|
35
|
Ornstein DL, Nervi AM, Rigas JR. Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer. Thoracic Oncology Program. Ann Oncol 1999; 10 Suppl 5:S35-40. [PMID: 10582137 DOI: 10.1093/annonc/10.suppl_5.s35] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Docetaxel is one of the most active single agents for the treatment of non-small-cell lung cancer. Given the preclinical indications for synergy and the lack of cross-resistance with other active agents in this disease, clinical trials of docetaxel combinations have been undertaken. Phase I and II clinical trials of docetaxel in combination with cisplatin, carboplatin, gemcitabine, vinorelbine, or thoracic radiation for patients with non-small-cell lung cancer were reviewed. The endpoint for phase I trials was to define the phase II doses for the docetaxel combinations where overall response rates, median and one year survival were the endpoints. Five phase I-II studies of docetaxel and cisplatin have reported response rates ranging from 21% to 48%. Median survival times ranged from 8 to 13 months, and one-year survivals from 32% to 58%. Combining docetaxel with vinorelbine resulted in a 37% response rate and a median survival of 9.4 months. Docetaxel in combination with gemcitabine produced a response rate of 53%. The adverse events of these combinations were manageable. Responses have also been reported in studies of docetaxel administered with carboplatin or thoracic radiation therapy. Combinations of docetaxel with platinum, vinorelbine, gemcitabine, and radiation were active in non-small-cell lung cancer with acceptable adverse effects. Phase III trials are currently in progress to further define the role of docetaxel combinations in the first-line treatment of this disease.
Collapse
Affiliation(s)
- D L Ornstein
- Norris Cotton Cancer Center, Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
| | | | | |
Collapse
|
36
|
Ornstein DL, Pipas JM, Rigas JR. Recent advances in cancer chemotherapy. Acad Radiol 1999; 6:696-705. [PMID: 10894074 DOI: 10.1016/s1076-6332(99)80120-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- D L Ornstein
- Department of Medicine, Dartmouth-Hitchcock Medical Center, The Norris Cotton Cancer Center, Lebanon, NH, USA
| | | | | |
Collapse
|
37
|
Abstract
The options for treating non-small cell lung cancer (NSCLC) were expanded by the introduction of the taxanes. As a single agent, docetaxel produced response rates ranging from 15 to 22% in evaluable patients in the second-line setting, with median duration of responses ranging from 5.6 to 7.5 months. To confirm the results observed in the phase II studies, a phase III trial was conducted. Three-hundred and seventy-three patients with advanced NSCLC who had failed prior platinum-based chemotherapy were randomized to receive docetaxel 100 mg/m2, docetaxel 75 mg/m2 or a reference arm consisting of vinorelbine or ifosfamide. Efficacy, safety and quality of life (using the Lung Cancer Symptom Scale) were assessed. Data from this study are forthcoming and may confirm the benefits provided by the inclusion of docetaxel in the second-line treatment of NSCLC. Docetaxel is also an active single agent in the first-line setting, with response rates ranging from 24 to 38% in evaluable patients, with a median survival of 6-13 months. Based on the single-agent activity, it was logical to evaluate the efficacy of docetaxel in combination with other active agents. As such, docetaxel has been studied in with numerous other agents such as vinorelbine, gemcitabine, platinums, etc. Notably cisplatin and carboplatin has shown promising rates of response and response duration in phase II trials. These combinations have now entered randomized phase III study.
Collapse
Affiliation(s)
- F Fossella
- MD Anderson Cancer Center, Houston, Texas 77030-4009, USA.
| | | | | |
Collapse
|
38
|
Eastman A, Rigas JR. Modulation of apoptosis signaling pathways and cell cycle regulation. Semin Oncol 1999; 26:7-16; discussion 41-2. [PMID: 10585003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
Apoptosis can be described as multiple pathways converging from numerous different initiating events and insults, such as anticancer agents. These pathways converge on a common irreversible execution phase in which proteases and nucleases digest the doomed cell. Counteracting the signals to die are a variety of pathways that enhance cell survival and that may become constitutively active as a result of oncogenic transformation. Studies of apoptosis have identified many cellular factors that play a role in the decision as to whether a cell lives or dies. These factors include the p53 tumor suppressor, the Bcl-2 family of proteins, and a variety of intracellular signal transduction pathways, all of which may provide novel therapeutic targets. It also is possible to take advantage of the defect in cell cycle regulation that occurs in cells with mutant p53; such cells are susceptible to agents that inhibit DNA damage-induced cell cycle checkpoints at S and G2 phase. Cell cycle perturbation occurs following treatment with all anticancer drugs and a knowledge of the kinetics of such events should facilitate design of synergistic rather than antagonistic schedules. These concepts have been developed in cell culture models and it is essential to determine whether the mechanisms defined also occur in patients receiving therapy. Accordingly, tumors need to undergo serial biopsies during therapy and be analyzed for perturbation in cell cycle or apoptosis-regulating proteins. The results of such studies should facilitate the rational design of chemotherapy combinations.
Collapse
Affiliation(s)
- A Eastman
- Norris Cotton Cancer Center, The Department of Pharmacology, Dartmouth Medical School, Hanover, NH 03755-3835, USA
| | | |
Collapse
|
39
|
Bengtson EM, Rigas JR. A brief historical review of the development of chemotherapy for the treatment of advanced non-small cell lung cancer: why we should look beyond platinum. Semin Oncol 1999; 26:1-6. [PMID: 10585002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
We are approaching the end of the fifth decade and the most productive period in the development of chemotherapy for the treatment of advanced non-small cell lung cancer. We began this decade by establishing cisplatin-based combination chemotherapy regimens of the 1980s as effective at improving survival for patients with advanced disease. The observed improvement in survival from these trials appears to be primarily attributed to cisplatin. Furthermore, this decade, unlike the prior, has identified an abundance of novel active agents for the treatment of this disease. Vinorelbine, gemcitabine, docetaxel, paclitaxel, and irinotecan are all new chemotherapeutic agents which have shown promising activity in this disease. In contrast to the cisplatin-based chemotherapy trials of the 1980s, these newer chemotherapeutic agents when given in combination with cisplatin add to the survival outcomes for these patients. With these survival advances has come a focus on chemotherapy-induced adverse events, lung cancer symptom management, and overall quality of life. The results of the cisplatin combination trials will be discussed.
Collapse
Affiliation(s)
- E M Bengtson
- Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH 03755, USA
| | | |
Collapse
|
40
|
Dragnev KH, Rigas JR. The future beyond platinum for the treatment of advanced non-small cell lung cancer. Semin Oncol 1999; 26:73-6. [PMID: 10585012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
The development of chemotherapy for advanced non-small cell lung cancer has been most productive in its fifth decade. We began this decade by establishing cisplatin-based combination chemotherapy regimens of the 1980s as effective at improving survival for patients with advanced disease. The observed improvement in survival from these trials appears to be primarily attributed to cisplatin. Furthermore, this decade, unlike the prior, has identified an abundance of novel active agents for the treatment of this disease. Vinorelbine, gemcitabine, docetaxel, paclitaxel, and irinotecan are all new chemotherapeutic agents which have shown promising activity and their cisplatin combinations have further advanced survival for these patients. In contrast to the cisplatin-based chemotherapy trials of the 1980s, these newer chemotherapeutic agents, when given in combination with cisplatin, add to the survival outcomes for patients with advanced non-small cell lung cancer. With these survival advances has come a focus on chemotherapy-induced adverse events, lung cancer symptom management, and overall quality of life. Is it feasible to use these novel chemotherapeutic drugs as single-agents, sequentially or as nonplatinum combinations to prolong survival, minimize adverse events, control symptoms, and improve the quality of life for patients with this disease? The goal of this symposium will be to present the results of the single-agent and nonplatinum combination studies of these newer therapies with a focus on survival, symptom management, and quality of life. This symposium is intended to introduce the next decade of care for advanced non-small cell lung cancer, namely "Non-platinum-Based Chemotherapy."
Collapse
Affiliation(s)
- K H Dragnev
- Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH 03755, USA
| | | |
Collapse
|
41
|
Rigas JR, Kris MG, Miller VA, Pisters KM, Heelan RT, Grant SC, Fennelly DW, Chou TC, Sirotnak FM. Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors. Ann Oncol 1999; 10:601-3. [PMID: 10416013 DOI: 10.1023/a:1026404812699] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The antifolate edatrexate and the microtubule-stabilizing agent paclitaxel have both demonstrated single-agent activity in lung and breast cancer. In vitro, the sequential combination of edatrexate followed by paclitaxel produced synergistic antitumor effects. This trial was designed to find the maximum tolerated doses of edatrexate and paclitaxel when given every two weeks utilizing this sequential schedule. PATIENTS AND METHODS Thirty-four patients with solid tumors received edatrexate intravenously on days 1 and 15 and paclitaxel intravenously as a three-hour infusion on days 2 and 16 of each 28-day cycle. Edatrexate was escalated from 40 to 120 mg/m2 and the paclitaxel dose fixed at 135 mg/m2. When the maximum-tolerated dose was not reached, edatrexate was fixed at 120 mg/m2 and paclitaxel escalated to 175 and 210 mg/m2. RESULTS All 34 patients were assessable. The maximum tolerated doses were 120 mg/m2 of edatrexate and 210 mg/m2 of paclitaxel. Grade 3 myalgia, peripheral neuropathy, leukopenia, and an infusion-related reaction occurred. Eight patients with non-small-cell lung cancer and one with bladder cancer achieved major objective responses. CONCLUSIONS The recommended phase II doses are 120 mg/m2 of edatrexate days 1 and 15 and 175 mg/m2 of paclitaxel as a three-hour infusion days 2 and 16 of a 28 day cycle. These results warrant phase II trials of the combination leading to phase III studies comparing the two drugs to a single agent to confirm the preclinical evidence of synergy.
Collapse
Affiliation(s)
- J R Rigas
- Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Rathmann J, Leopold KA, Rigas JR. Daily paclitaxel and thoracic radiation therapy for non-small cell lung cancer: preliminary results. Semin Radiat Oncol 1999; 9:130-5. [PMID: 10210552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
Platinum-based combination chemotherapy plus thoracic radiation prolongs survival for patients with stage III non-small cell lung cancer. Paclitaxel demonstrates significant clinical antitumor activity in this disease and potentiates the effects of ionizing radiation by arresting cells at the sensitive G2/M cell cycle phase. The optimal schedule of paclitaxel administered concomitantly with thoracic radiation has not been established. The preliminary results of this phase I trial, which was designed to define the dose-limiting adverse event and the maximum tolerated dose of paclitaxel administered daily before each fraction of thoracic radiation, are being presented. Twenty-nine patients with inoperable clinical stage II to IIIB non-small cell lung cancer received two 21-day cycles of primary chemotherapy with carboplatin and paclitaxel. Six weeks from the initiation of therapy, daily paclitaxel was administered intravenously over 1 hour without premedication before 68 Gy of thoracic radiation in 34 fractions. Twenty-six patients completed concomitant daily paclitaxel with radiation and are evaluable for toxicity. Early radiation esophagitis was the dose-limiting toxicity at the 15 mg dose level. A daily paclitaxel dose of 10 mg or 6 mg/m2 and 68 Gy of thoracic radiotherapy are recommended for further study. Preliminary data from this dose-escalation trial suggest that this combined modality treatment with concurrent radiation and daily paclitaxel following primary induction therapy for stage II to III non-small cell lung cancer is feasible. The observed adverse effects within the radiation field suggest active radiosensitization by low-dose daily paclitaxel.
Collapse
Affiliation(s)
- J Rathmann
- Thoracic Oncology Program, Norris Cotton Cancer Center, Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756-0001, USA
| | | | | |
Collapse
|
43
|
Ornstein DL, Nervi AM, Rigas JR. Ann Oncol 1999; 10:35-40. [DOI: 10.1023/a:1008395904082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
44
|
Rigas JR. Do newer chemotherapeutic agents improve survival in non-small cell lung cancer? Semin Oncol 1998; 25:5-9. [PMID: 9704669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Cisplatin-based chemotherapy regimens used in the 1980s led to a small but significant prolongation of survival for patients with advanced non-small cell lung cancer (NSCLC), achieving median survival of approximately 7 months compared with the 4 months seen with best supportive care. Vinorelbine, docetaxel, and gemcitabine are new drugs with promising activity in NSCLC. For each of these drugs, median survivals in excess of 7 months have been reported in single-agent studies. When they are used in combination with cisplatin, 10-month median survivals have been achieved. In addition, docetaxel appears capable of inducing responses and prolonging survival when used as second-line therapy in patients who have failed platinum therapy. The combination of these new agents with cisplatin or with each other may further improve survival prospects for patients with advanced NSCLC.
Collapse
Affiliation(s)
- J R Rigas
- Norris Cotton Cancer Center, Department of Medicine, Dartmouth-Hitchock Medical Center, Lebanon, NH 03756-0001, USA
| |
Collapse
|
45
|
Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16:187-96. [PMID: 9440742 DOI: 10.1200/jco.1998.16.1.187] [Citation(s) in RCA: 332] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
PURPOSE The population pharmacokinetic/pharmacodynamic (PK/PD) approach was prospectively integrated in the clinical development of docetaxel to assess the PK profile in a large population of patients and investigate systemic exposure as a prognostic factor for clinical outcome. PATIENTS AND METHODS PK analysis was performed at first course in 24 phase II studies of docetaxel monotherapy using four randomized limited-sampling schedules. Bayesian estimates of clearance (CL), area under the concentration-time curve (AUC), and peak and duration of plasma levels greater than threshold levels were used as measures of exposure. PD data included for efficacy, response rate, time to first response, and time to progression (TTP) in breast cancer and non-small-cell lung cancer (NSCLC), and for toxicity, grade 4 neutropenia, and febrile neutropenia at first course and time to onset of fluid retention. PK/PD analysis was conducted using logistic and Cox multivariate regression models. RESULTS PK protocol implementation was successful. Most of the patients registered (721 of 936, 77%) were sampled and 68% were assessable for PK (640 patients). First-course docetaxel AUC was a significant predictor (P = .0232) of TTP in NSCLC (n = 151). Docetaxel CL was a strong independent predictor (P < .0001) of both grade 4 neutropenia and febrile neutropenia (n = 582). Cumulative dose was the strongest predictor (P < .0001) of the time to onset of fluid retention (n = 631). However, the duration of exposure over 0.20 micromol/L (0.16 microg/mL) at first course was an independent predictor (P = .0029). Few patients (n = 25, 4%) received the recommended dexamethasone premedication. CONCLUSION First-course docetaxel PK is a predictor of first-course hematologic toxicity, but also of fluid retention, which is cumulative in nature. Patients with elevated hepatic enzymes have a 27% reduction in docetaxel CL and are at a higher risk of toxicity. A starting dose of 75 mg/m2 is currently being evaluated in this population. Prospective implementation of large-scale population PK/PD evaluation is feasible in early drug development and this approach generates clinically relevant findings.
Collapse
Affiliation(s)
- R Bruno
- Drug Metabolism and Pharmacokinetics Department, Rhône-Poulenc Rorer, Antony, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Miller VA, Benedetti FM, Rigas JR, Verret AL, Pfister DG, Straus D, Kris MG, Crisp M, Heyman R, Loewen GR, Truglia JA, Warrell RP. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 1997; 15:790-5. [PMID: 9053506 DOI: 10.1200/jco.1997.15.2.790] [Citation(s) in RCA: 140] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
PURPOSE The retinoid response is mediated by nuclear receptors, including retinoic acid receptors (RARs) and retinoid "X" receptors (RXRs). All-trans retinoic acid (RA) binds only RARs, while 9-cis RA is an agonist for both RARs and RXRs. Recently, LGD1069 was identified as a highly selective RXR agonist with low affinity for RARs. We undertook a dose-ranging study to examine the safety, clinical tolerance, and pharmacokinetics of LGD1069 in patients with advanced cancer. PATIENTS AND METHODS Fifty-two patients received. LGD1069 administered orally once daily at doses that ranged from 5 to 500 mg/m2 for 1 to 41 weeks. Treatment proceeded from a starting dose of 5 mg/m2. Pharmacokinetic sampling was performed on selected patients on days 1, 15, and 29. RESULTS Reversible, asymptomatic increases in liver biochemical tests were the most common dose-limiting adverse effect. Less prominent reactions included leukopenia, hypertriglyceridemia, and hypercalcemia. Characteristic retinoid toxicities, such as cheilitis, headache, and myalgias/arthralgias, were mild or absent. Two patients with cutaneous T-cell lymphoma experienced major antitumor responses. Pharmacokinetic studies obtained in 27 patients at eight dose levels showed that the day 1 area under the plasma concentration-times-time curves (AUCs) were proportional to dose. At all doses studied, the day 1 AUCs were similar to those on days 15 and 29, indicating a lack of induced metabolism. CONCLUSION LGD1069 is a unique compound that exploits a newly identified pathway of retinoid receptor biology that may be relevant to tumor-cell proliferation and apoptosis. Further investigation of this drug is warranted. Based on the results of this study, a dose of 300 mg/m2 is recommended for single-agent trials.
Collapse
Affiliation(s)
- V A Miller
- Department of Medicine, Memorial Sloan-Kettering Cancer Center and Cornell University Medical College, New York, NY 10021, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Miller VA, Rigas JR, Tong WP, Reid JR, Pisters KM, Grant SC, Heelan RT, Kris MG. Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer. Cancer Chemother Pharmacol 1997; 40:415-8. [PMID: 9272118 DOI: 10.1007/s002800050679] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
PURPOSE Chloroquinoxaline sulfonamide (CQS) was one of the first agents identified by the human tumor colony-forming assay (HTCFA) as possessing antitumor activity in non-small-cell lung cancer (NSCLC). Prior phase I studies had suggested that plasma concentrations equivalent to those showing efficacy in the HTCFA could be reliably attained in humans. This phase II study assessed the antitumor activity of CQS while using an adaptive control pharmacokinetic modelling system to attain targeted plasma levels of this novel compound. METHODS A group of 20 patients with stage III or IV NSCLC received CQS as a 1-h weekly infusion at an initial dose of 2 g/m2. In all patients, 24-h plasma concentrations of CQS were measured. Patients with levels < 100 micrograms/ml had dose increases determined by their 24-h levels and pharmacokinetic parameters obtained from two prior phase I trials of this agent. These individuals had 24-h CQS levels repeated after their second weeks' treatment and doses were readjusted if the target concentration was not reached. Antitumor response assessment was made every 6 weeks. RESULTS Of the 20 patients, 18 attained the target plasma concentration, and 16 of these achieved this initially or with just one dose adjustment. No major objective antitumor responses were observed (major response rate 0%, 95% CI 0-17%). CQS was well tolerated with hypoglycemia being the most clinically significant toxicity. CONCLUSIONS When given on this schedule CQS is inactive in NSCLC despite the fact that the target concentration was achieved in 90% of patients. The ability of the HTCFA to identify active agents remains unproved.
Collapse
Affiliation(s)
- V A Miller
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Abstract
BACKGROUND Early detection and surgical resection offers the highest likelihood of cure for patients with lung cancer. Patients presenting at the extremes of age may fail to benefit maximally from these interventions. To study the impact of age on stage, histology, symptom, and treatment of patients with non-small cell lung cancer, we undertook a retrospective review. METHODS One thousand eight hundred two patients with non-small cell lung cancer were identified between 1983 and 1993. Patients were selected by age as less than 45 years (55 patients) and 80 years or more (108 patients), and their medical records were reviewed. RESULTS Three younger patients (6%) presented with stage I or II disease, yet 15 (32%) underwent thoracic operation. Twenty-seven elderly patients (33%) presented with early stage disease and only 6% underwent operation. The median survival was significantly longer for the younger population with surgically resectable stages of disease (stage I to IIIA) (p < 0.05), whereas no significant difference in survival was seen for the two groups with advanced disease (stage IIIB and IV). CONCLUSIONS Age significantly affects the presentation and treatment of non-small cell lung cancer patients. Although thoracic operation imparts the greatest survival advantage, this benefit is diminished due to advanced disease in the younger patients and lack of surgical intervention in the elderly.
Collapse
Affiliation(s)
- W C Nugent
- Department of Surgery, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756-0001, USA
| | | | | | | | | | | |
Collapse
|
49
|
Pisters KM, Tyson LB, Tong W, Fleisher M, Miller VA, Grant SC, Pfister DG, Rigas JR, Densmore CL, Krol G, Heelan RT, Sirotnak FM, Bertino JR, Kris MG. High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer. Clin Cancer Res 1996; 2:1819-24. [PMID: 9816135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
Our objective was to determine the maximum tolerated dose and toxicity of i.v. edatrexate with p.o. leucovorin. Thirty-one adults with advanced solid tumors received edatrexate as a 2-h infusion, once a week for 3 weeks, recycled every 28 days. p.o. leucovorin (10 mg/m2, every 6 h for 10 doses) began 24 h later. All had urinary alkalinization and p.o. hydration. Nine dosage levels ranging from 120 to 3750 mg/m2 were explored. Fatigue, epistaxis, nausea/emesis, mucositis, rash, myalgias, leukopenia, thrombocytopenia, and transient elevations of serum aspartate transferase were observed. Leukoencephalopathy with clinical manifestations occurred in two patients (one had prior cranial irradiation). Pharmacokinetic studies carried out at the 120- and 1080-mg/m2 dose levels revealed no significant difference in the elimination half-life at the two dose levels studied and no significant intrapatient variability between day 1 and day 8 edatrexate administration. Serum edatrexate levels measured using a dihydrofolate reductase inhibition assay correlated with those by high-performance liquid chromatography. Three major and two minor antitumor responses occurred. The maximum tolerated dose was 3750 mg/m2, with grade 3 or 4 leukopenia (one patient), stomatitis (one patient), and leukoencephalopathy (one patient). Because of the occurrence of leukoencephalopathy, further study of high-dose edatrexate with leucovorin rescue is not recommended.
Collapse
Affiliation(s)
- K M Pisters
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Laboratory of Molecular Pharmacology and Therapeutics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Rigas JR, Miller VA, Zhang ZF, Klimstra DS, Tong WP, Kris MG, Warrell RP. Metabolic phenotypes of retinoic acid and the risk of lung cancer. Cancer Res 1996; 56:2692-6. [PMID: 8665495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The metabolic activity of cytochrome P-450 enzymes has been associated with an increased risk of developing lung cancer. We found previously that all-trans retinoic acid is catabolized by these oxidative enzymes, and that an inhibitor of this system discriminated between two populations of lung cancer patients. We examined the association between this metabolic phenotype and the risk of lung cancer in 85 subjects. The area under the plasma concentration x time curve (AUC) was calculated after a single oral dose of all-trans retinoic acid (45 mg/m2). The mean AUC for patients who had either squamous or large cell carcinomas was significantly lower than that of patients with adenocarcinomas (P = 0.0001) or control subjects (P = 0.01). Individuals with an AUC < 250 ng x h/ml had a greater likelihood of having squamous or large cell carcinoma (odds ratio = 5.93). This study suggests that the "rapid" catabolism of all-trans retinoic acid is linked to an increased risk of squamous or large cell cancers of the lung.
Collapse
Affiliation(s)
- J R Rigas
- Thoracic Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
| | | | | | | | | | | | | |
Collapse
|